BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
The main objective of this prospective study is to assess the clinical outcomes of platinum based chemotherapy cases either cisplatin or carboplatin according to BRCA status in neoadjuvant and recurrent ovarian cancer.
- EligibilityCriteria: Inclusion Criteria:  Age above 18 years, Pathologically proven ovarian cancer,epithelial origin. BRCA mutant/wild Recurrent cases who are eligible to anti-VEGF (Bevacizumab). Patients with clinical stages T1-T3c , N0-N1b, M0, and recurrent platinum sensitive cases. Patients with good renal and liver functions. No other malignancy (double malignancy). Performance status 0-2 according to ECOG performance status scale.  Exclusion Criteria:  Performance status 3-4 according to ECOG performance status scale. Patients refuse to receive chemotherapy, Patients not eligible to receive chemotherapy due to liver or renal impairment. - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Ovarian cancer patients - SamplingMethod: Non-Probability Sample